It’s just 18 months since Sysmex acquired flow cytometry specialists Partec, but the new company has clearly struck a chord with its (potential) clients. Specialists for cell counting in essential healthcare, research and industry, the company enjoyed an overly full booth at this year’s flow cytometry fair CYTO. Visitors were especially interested in the company’s various CyFlow® solutions, particularly in essential healthcare, and in discovering the new opportunities presented by the established global Sysmex network.
Pure flow cytometry is a relatively new area of expertise for the Sysmex Corporation, but visitors to this year’s most important FCM fair can clearly see the benefits of the company’s latest acquisition. By adding Sysmex’s resources and established, trusted network to former Partec’s deep knowledge and expertise, the potential is huge. And hundreds of visitors were keen to discover the latest developments and view the full range of Sysmex Partec solutions.
While HIV/AIDS is now ‘merely’ a chronic disease in the wealthy West, it remains a devastating killer in poorer areas of the world. With its affordable monitoring solutions, Sysmex Partec can now offer even more support to combat this devastating disease thanks to its CyFlow® Counter solutions. Industry and research that need cell counting solutions are equally going to benefit from the new cooperation as was illustrated, for example, with Sysmex Partec’s advanced ploidy analysers and the application of its CyFlow® Cube and CyFlow® Space analysers.
Ms Rikke Rytter, Senior Vice President Marketing EMEA at Sysmex Europe: “The opportunities we have gained with the acquisition of Sysmex Partec, and especially the remarkable knowledge and expertise within the company, are clearly going to help us further fulfill our mission of shaping the advancement of healthcare. We now have superb solutions for combating HIV/AIDS, malaria and TB, and the potential in clinical and research applications are huge. We were delighted by the overwhelming interest at this year’s CYTO, and look forward to providing further answers to our clients’ challenges over the years to come.”